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Abstract
Parkinson’s disease (PD) patients often suffer from non-motor symptoms like sleep dysregulation, mood disturbances
or circadian rhythms dysfunction. The melanopsin-containing retinal ganglion cells are involved in the control
and regulation of these processes and may be affected in PD, as other retinal and visual implications have been
described in the disease. Number and morphology of human melanopsin-containing retinal ganglion cells were
evaluated by immunohistochemistry in eyes from donors with PD or control. The Sholl number of intersections,
the number of branches, and the number of terminals from the Sholl analysis were significantly reduced in PD
melanopsin ganglion cells. Also, the density of these cells significantly decreased in PD compared to controls.
Degeneration and impairment of the retinal melanopsin system may affect to sleep and circadian dysfunction
reported in PD pathology, and its protection or stimulation may lead to better disease prospect and global quality of
life of patients.
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Introduction
The retina is an accessible and visible tissue, part of the
central nervous system (CNS). Its well defined and
highly characterized layered structure, together with
the extensive knowledge about its neurons, synaptic
contacts and physiology, make the retina an ideal
material for pathophysiological studies of the CNS. In
fact, neurodegenerative diseases mainly observed in the
brain such as Parkinson’s disease (PD), Alzheimer’s dis-
ease, or Multiple Sclerosis present similar signs of de-
generation in the retina [14], which is considered as a
“window to the brain”.
Intrinsically photosensitive melanopsin-containing ret-
inal ganglion cells (mRGCs) are, together with cones
and rods, retinal photoreceptors. While cones and rods
are responsible for vision forming pathways, mRGCs are
also in charge of the non-image forming pathways that
primarily control and measure light irradiance detection
[27, 48]. Melanopsin, an opsin protein containing a vita-
min A-based chromophore maximally sensitive at
479 nm [40, 47], is the photopigment contained within
mRGCs. Melanopsin-containing RGCs project to differ-
ent CNS regions and regulate physiological and behav-
ioral responses as important as circadian rhythms,
pupillary reflex, melatonin production or mood [28, 30].
PD is the second most common neurological
disorder and affects over 10 million people worldwide
(http://parkinson.org/understanding-parkinsons/cau-
ses-and-statistics). Its main motor clinical features are
rigidity, tremor and bradykinesia [19, 21, 46], but
people with PD may also have several non-motor
symptoms including cognitive decline and dementia
[11], gastrointestinal and cardiovascular problems
[43], mood disturbance [50], visual disruption [2, 55],
impairment of the pupillary reflex response [54], and
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sleep disorders [19, 46]. Sleep disorders including
REM sleep behavior disorder (RBD), altered sleep, and
hypersomnolence are extremely common in PD
patients, affecting up to a 90% [10, 56]. Moreover,
people with PD also exhibit alterations in the circadian
secretion pattern of melatonin [9]. Dysfunction of cir-
cadian rhythms in PD is thought to be one of the
causes of sleep disturbances and it can lead to cogni-
tive and metabolic deficits, psychiatric and mood
symptoms, or cardiovascular problems, negatively
impacting quality of life [56].
The defining pathological lesions of PD are Lewy
bodies and associated neurites with cytoplasmic accu-
mulation of α-synuclein phosphorylated at serine-129
(p-α-syn), and the loss of dopaminergic neurons in the
substantia nigra pars compacta [5, 13, 19]. The latter
has traditionally been considered the cause of the
motor clinical manifestations. Nevertheless, PD is today
mostly considered as a multisystem disorder in which
other different nervous system subdivisions are af-
fected. Brain regions involved in vision are affected in
PD, including the hypothalamic suprachiasmatic nu-
cleus [16] and the retina [6, 45], both of which exhibit
p-α-syn deposits. This visual system pathology in PD is
accompanied by clinical findings including reduced
electroretinography response and reduced visual evoked
potentials, lower contrast sensitivity and impaired color
and motion perception [3, 39]. These all suggest that vi-
sion is strongly affected at a cellular level.
As retinal mRGCs innervate the suprachiasmatic
nucleus [20] and are jointly responsible for regulating
circadian rhythms, which are in turn involved in mood
and sleep behaviors, mRGCs dysfunction may be at
least partially involved in the PD pathological process.
Others have previously proposed a link between
mRGCs, circadian rhythms and sleep regulation [1,
32], and a relationship between sleep disturbances and
morphological impairment of mRGCs in human with
aging has been described [18]. Therefore, the aim of
this study was to evaluate the morphological changes
of human mRGCs in PD, hypothesizing an involve-
ment in sleep and circadian dysfunction. In this work,
we show that the retinal melanopsin system is im-
paired in PD. We demonstrate that mRGCs degener-
ate in PD, as revealed by its number reduction and
their morphological alterations, and this fact may be
linked to the circadian and sleep disturbances suffered
by PD patients.
Materials and methods
Human retinas
Human retinas from 11 donors were obtained postmor-
tem, within 6 h of death, from the Arizona Study of
Aging and Neurodegenerative Disorders (AZSAND), the
Banner Sun Health Research Institute Brain and Body
Donation Program (BBDP; http://www.brainandbodydo-
nationprogram.org/). All procedures were in accordance
with the Declaration of Helsinki and with the recom-
mendations and protocols approved by the Ethics Com-
mittee of the University of Alicante. Signed written
informed consent was provided by all the participants in
the study. Human donors, both men and women, were
not significantly different in age, ranging from 70 to
82 years at death, and did not report any past history of
retinal diseases.
The control group consisted of patients without
neurodegenerative diseases (n = 5) and the Parkinson’s
disease group (n = 6) included subjects with a typical
clinicopathological profile, diagnosed from the BBDP.
Standard tests and neuropathological examinations
were performed in deceased subjects as previously
described [7].
Retinal histology
The human enucleated eyes were fixed in formaldehyde
(3,75–4%) for 2 h at room temperature or 24–72 h at 4 °
C, washed in PBS and then successively cryoprotected in
increasing sucrose solutions of 15%, 20% and 30%. After
removing the iris, lens and vitreous body, the retina was
extracted and dissected, obtaining eight quadrants. The
superior-nasal portion was used for further analysis.
Immunoperoxidase labeling
Wholemount retinas were stained using the immunoperox-
idase labeling technique described by Esquiva et al. [17, 18].
Following inactivation of endogenous peroxidase activity
with 1% H2O2 (H1009; Sigma, St. Louis, MO, USA), retinas
were incubated in 2.28% NaIO4 (S1878; Sigma) and later in
0.02% NaBH4 (163314; Panreac, Barcelona, Spain). Then,
flat-mount retinas were incubated in the anti-melanopsin
primary antibody (1:5000; UF028) for 3 days at 4 °C. This
antibody, raised against the 15 N-terminal amino acids of
human melanopsin, was kindly provided by Dr. Ignacio
Provencio (University of Virginia, Charlottesville, VA,
USA). After the incubation time, they were washed in PBS,
incubated for 2 days in a goat anti-rabbit biotinylated
secondary antibody (1:100; 111–064-9144; Jackson Immu-
noResearch Laboratories, West Grove, PA, USA), and then
incubated 2 more days in an avidin-biotin peroxidase
complex solution (0.9% avidin + 0.9% biotin; PK-6100, Vec-
tastain Elite ABC Kit; Vector Laboratories Ltd., Cambridge-
shire, UK). Retinas were finally washed and incubated in a
fresh solution of 0.1% 3,3′-diaminobenzidine tetrahydro-
chloride (DAB, D5637; Sigma) plus 0.01% H2O2 and
0.025% ammonium nickel (II) sulfate hexahydrate (A1827;
Sigma) until the staining was revealed as a brown precipi-
tate. After DAB reaction, flat retinas were prepared with
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the ganglion cell layer side up, and coverslipped for optical
microscopy (Leica DMR; Leica Microsystems).
To determine their type and morphology, immuno-
stained mRGCs were traced by hand in all flat-mounted
retinas using a camera lucida connected to a Leica DMR
microscope (Leica Microsystems). Images were then dig-
itized, using image-editing software (Adobe Photoshop
10.0; Adobe Systems, Inc., San Jose, CA, USA). Total
number of cells expressing melanopsin was counted and
density of mRGCs per mm2 was calculated.
Morphological analysis
Representative mRGCs were traced by hand in order to
recreate their soma and dendritic profiles using a camera
lucida (120 cells analyzed in total, 60 cells of controls
and 60 of PD, 15 cells of each morphological subtype
and group).
To analyze the morphology of mRGCs the Bonfire
program developed in the Firestein laboratory at Rutgers
University [33] was used. From digitized neuritic arbors,
this software allowed us to perform a Sholl analysis and
to estimate the number of branch points, the terminal
neurite tips and the total number of Sholl intersections
per cell [49].
Statistical analysis
Statistical analysis was performed using Prism 6 for
Windows (Graphpad Software, Inc., La Jolla, CA, USA).
To assess the differences of the studied variables, both
globally or per mRGC subtype (M1, M1d, M2 and M3),
between PD and control patients a non-parametric
two-tailed Mann-Whitney test was used. Differences of
the Sholl curve representing the number of intersections
per distance between PD and controls were evaluated
using a paired non-parametric Wilcoxon signed rank
test. In all cases, a p-value lower than 0.05 was consid-
ered statistically significant.
Results
Types of mRGCs in the human retina
In the human retina, four types of mRGCs are found.
They are classified in accordance with their soma loca-
tion and dendritic stratifications: M1, M1d, M2, and
M3. As the diagram of Fig. 1 shows, M1, M2 and M3
cells have their soma located in the ganglion cell layer,
while their dendrites stratify in different strata of the
inner plexiform layer (IPL). M1 cells stratify in the S1
plexus of the IPL, M2 stratify in S5 plexus, and M3
has dendrites in both strata: S1 and S5. M1d cell is a
displaced M1 cell, with its soma located in the inner
nuclear layer (INL) and its dendrites in the S1 plexus
of the IPL, near the INL [8]. M1d mRGC is the pre-
dominant type in the human retina, accounting for
about half of all mRGCs [18, 25]. An example of con-
trol and PD DAB immunostained M1d mRGC is
shown in Fig. 1a and b respectively. Notice the lower
dendrite complexity in PD mRGC (Fig. 1b) and its
lower staining intensity when compared to controls
(Fig. 1a). Identification of S1 and S5 strata can be done
changing the microscope focus and using the
Fig. 1 Melanopsin retinal ganglion cells in the human retina. a Diagram showing the structure and classification of mRGC depending on their
soma location and dendrites stratification in IPL S1 or S5. b, c Immunostaining of human melanopsin using the DAB method in flat wholemount
retinas of control (b) and PD (c) subjects. Scale bar, 50 μm
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Nomarski technique of differential interference con-
trast. This technique allows us to identify and differ-
entiate the INL, the IPL, and the ganglion cell layer
(GCL). Thus, S1 and S5 strata can be differentiated,
without need of counterstaining, because S1 is near
the INL and S5 in the opposite side of the IPL, near
the GCL.
Decrease of mRGC density in PD retinas
Cell density quantification and morphological analysis
were performed to evaluate differences in mRGCs be-
tween PD and control subjects. These studies were made
considering the total mRGCs as well as differentiating
by mRGC type. A reduction in the mRGC density and
in the complexity of the melanopsin plexus was found.
Fig. 2a and b are drawings representing retinal fields that
show mRGCs and its plexus in control and PD. Fig. 2c
and d show the density of mRGCs, expressed as number
of mRGCs per mm2, both totally and by mRGC type. A
reduction in number of mRGCs, accompanied by a dras-
tic reduction in their plexus complexity, can be clearly
seen in the drawings. The decrease in mRGC number is
statistically significant (control: 4.8 ± 1.3 cells/mm2; PD:
3.2 ± 0.8 cells/mm2; p-value = 0.05) and it mostly affects
the M1d and M2 mRGC types. In normal conditions,
mRGCs make contacts to other mRGCs creating a dense
plexus and have numerous dendritic beads, as the con-
trol drawing shows. In PD, the plexus is highly reduced
and there are very few contacts between cells and fewer
dendritic beads.
Morphological impairment of mRGCs in PD
Apart from cell density decline, morphological
changes were also found in PD mRGCs. Morphology,
dendritic arborization and dendritic tree size of nor-
mal and PD cells can be observed in Fig. 3. Red draw-
ings show the elements that are placed in the IPL S5
stratum and blue represent the elements from S1
stratum, allowing the differentiation of the mRGC
types. Visually, structure, size and dendritic trees are
altered in PD compared to controls: dendritic area is
reduced and cells have fewer and shorter ramifica-
tions. Dendritic beads, which are thought to represent
synaptic contact points, are also reduced in PD (con-
trol: 44.7±25.8 beads per cell; PD: 19.3±10.9 beads per
cell; p-value < 0.0001), what could be a sign of func-
tional alteration. These morphological alterations are
drastic in M1, M1d and M2 cells, while M3 cells seem
to be the least affected by the disease.
Morphological changes were measured using the Sholl
analysis, that includes the total number of intersections,
the number of intersections per distance, and terminal
points and branch points numbers. Results are shown in
Fig. 4 and corroborate the differences described above.
The three analyzed measures are significantly reduced in
PD, compared to controls: terminal points decrease from
16 ± 5 (controls) to 13 ± 4 (PD) (p-value < 0.001);
branch points from 13± 5 to 9± 4 (p-value < 0.0001);
and Sholl total number of intersections from 137,2 ±
41,3 to 106,8 ± 38,2 (p-value < 0.001). When comparing
these parameters in each cell type, M1d and M2 cells
show statistically significant reduced values in PD in the
three measures, M1 cells show a statistically significant
decrease in Sholl analysis and terminal points, and M3
were not significantly affected, although they present a
tendency for fewer terminal and branch points. The
Sholl analysis curve (Fig. 4g) shows the number of inter-
sections per distance from the cell soma. Less intersec-
tions have been found in PD until a distance from the
soma of 340 μm, what indicates a lower cell complexity
and less ramifications of PD mRGCs, as concluded also by
the less branches, terminal points, and number of total in-
tersections that they present in comparison to controls.
Discussion
In recent years, a huge effort has been made to study
the state and health of brain regions related to circa-
dian rhythms disturbances and sleep dysregulation, like
the suprachiasmatic nucleus, but these alterations are
not yet completely understood and some regions are
found not to be affected until advanced states of the
disease [22]. The study of the retinal mRGCs is a new
approach in trying to understand the cellular mecha-
nisms underlying circadian rhythms dysfunctions in PD
and may add valuable information to the current know-
ledge of the disease.
This study demonstrates a loss of melanopsin-im-
munoreactive RGCs in Parkinson’s disease compared
to control subjects. The density of mRGCs is signifi-
cantly decreased in PD patients, and the remaining
cells exhibit morphological alterations like decreased
Sholl area, fewer ramifications and terminal points,
and a reduced melanopsin-immunoreactive plexus.
These morphological changes and numerical reduction
demonstrate that mRGCs are affected in PD, probably
by dying or losing melanopsin production, and it is
likely that both of these would lead to functional im-
pairment. To the best of our knowledge, this is the
first study that describes alterations of mRGCs in PD.
A recent study in humans show that the mRGC dens-
ity and plexus decrease with age and correlate it with
the circadian rhythm dysfunction observed with aging
[18]. In the present study, the mRGC type most
affected is M1d, the main mRGC type in the human
retina; that is also the type most affected by age [18].
M2 cells also have lower cell densities and both M1
and M2 show altered morphological parameters. These
differences are not significant in the aging retina, but in
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Fig. 2 Representative drawings of control and PD retinal fields. Each color defines an individual mRGC. a Melanopsin plexus in a control
wholemount retina. b Melanopsin plexus in a PD wholemount retina. c Total mRGC quantification (number of mRGCs per mm2) and comparison
between control and PD subjects. d Comparison of the mRGC density per cell type in control and PD subjects. Scale bar, 100 μm. Data is
presented as mean ± s.d. *P < 0.05, **P < 0.01
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PD it seems that almost all mRGCs show morphological
abnormalities as well as a numerical decline. As mRGCs
innervate the suprachiasmatic nucleus [20], it is expected
that these morphological alterations lead to a dysfunction
mostly related with circadian rhythms, mood, and sleep;
and also with the pupillary reflex: the major mRGC func-
tions. Morphological and connectivity studies about
mRGCs have also demonstrated its relationship with
dopaminergic cells, which make contacts in the S1 strata
of the IPL with mRGC somas and dendrites, mainly with
Fig. 3 Representative drawings of control and PD mRGCs. Blue indicates the parts of the cell located in the S1 IPL layer and red shows the parts of the
cell located in the S5 IPL layer. a, b M1 mRGC in control and PD respectively. c, d M1d mRGC in control and PD respectively. e, f M2 mRGC in control
and PD respectively. g, h M3 mRGC in control and PD respectively. Scale bar, 100 μm
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the M1d type [38]. Diminution of dopamine levels in the
retina in PD [26] may be one of the causes of M1d cell de-
generation, as this would represent a loss of one of their
main synaptic inputs.
In animal models, MPTP-treated monkeys exhibit
dopaminergic system impairment and circadian rhythm
disruption with altered sleep/wake cycle, REM sleep im-
pairment and daytime sleepiness [15, 23, 51, 56]. Also, in
P23H blind rats, degeneration of mRGCs statistically
correlates with circadian rhythms impairment [34].
Other existing works that analyzed the effect of
parkinsonism in circadian rhythms described changes in
the expression of the “clock genes” [12], in circadian
melatonin secretion [9], in pupillary reflex [4, 54], de-
pression [57] and in REM sleep [10, 52], all directly or
indirectly controlled and affected by mRGCs. But the
Fig. 4 Morphological Sholl analysis of mRGCs in PD and controls. a, b Comparison of terminal points number per cell in PD and controls considering total
mRGC (a) or per cell type (b). c, d Comparison of the number of branch points in all mRCGs (c) and per cell type (d) in PD and controls. e, f
Sholl area comparison of PD and control mRGCs globally (e) and per cell type (f). Data is presented as mean ± s.d. *P < 0.05, **P < 0.01, ***P < 0.001,
****P < 0.0001. g Sholl analysis curve representing number of intersections per distance from soma, comparing total controls and PD mRGCs. Data is
presented as mean ± s.e.m.
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suprachiasmatic nucleus has been found to be un-
affected until advanced stages of the disease, suggesting
that there are other components of the circadian system
causing circadian abnormalities in PD [22]. Thus, it is easy
to question the implication of the retina, and specifically of
the mRGCs, in circadian dysfunction in PD, but until now
no cellular studies were available to determine its real con-
tribution. The retinal melanopsin system abnormalities de-
tected in PD in the present study help to explain some of
the circadian and sleep problems that are common in the
disease, as it probably contributes to or worsens them. The
loss of mRGCs have also been described in other neuro-
logical pathologies like Alzheimer’s disease and diabetic ret-
inopathy [31, 44] where its impairment is related to
circadian rhythm alterations and sleep disorders [32, 35].
There is growing evidence that circadian rhythm disor-
ders, normally accompanied by sleep disruption, not
only negatively affect the patients’ quality of life but may
also accelerate the progression of neurodegenerative dis-
ease pathology [41]. The identification and management
of these symptoms is therefore important not only for a
clinical benefit but perhaps also for modulation of dis-
ease progression. In this sense, knowing the effect that
the retina and mRGCs may have in the progression of
circadian disorders, eye protection should be recom-
mended to patients. Additionally, novel therapies using
light stimulation to synchronize circadian rhythms are
demonstrating beneficial results in PD [24, 29, 36].
Martino et al. found that long-term light therapy im-
proves sleep quality, reduces awakenings during the
night and increases the total sleep time [42]. Light ther-
apy was also found to be effective for excessive daytime
sleepiness and global sleep quality [53]. A cellular
explanation of this light therapy success might possibly
invoke the stimulation of mRGCs, leading to dopamine
release and to circadian rhythms synchronization, glo-
bally improving PD pathology [37].
Conclusions
In summary, the present work demonstrates that the
retinal melanopsin system is affected in PD. This fact
has clinical implications for PD-related circadian
rhythm alteration as well as for mood and sleep disor-
ders. Protecting the retina to prolong mRGC health
and using light therapies could be beneficial for the
maintenance of circadian rhythms and for improving
global life quality of patients.
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